MedTrace Logo

Evaluation of Ranibizumab in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy

NCT00516464 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2007-08-15

No results posted yet for this study

Summary

Evaluation of ranibizumab on the ease and procedure and complication in proliferative diabetic retinopathy (PDR) requiring vitrectomy.

Conditions

  • Proliferative Diabetic Retinopathy

Interventions

DRUG

Lucentis (ranibizumab)

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Retina Associates, Kansas City

    lead OTHER

Principal Investigators

  • Gregory M Fox, MD · Retina Associates, PA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Completion
2008-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00516464 on ClinicalTrials.gov